Andere Sprachen Sequana Medical N.V.

Aktien

A2PD78

BE0974340722

SEQUA

Realtime Euronext Bruxelles Andere Börsenplätze 09:00:17 03.06.2024			% 5 Tage	% 1. Jan.
1.6 ^EUR	0.00%		-0.31%	-60.00%

03.04.	Sequana Medical meldet überzeugende Daten aus DSR Proof-of-Concept Studien bei Herzinsuffizienz veröffentlicht im European Journal of Heart Failure	CI
28.03.	Sequana Medical NV berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure	03.04.
Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Sequana Medical NV Announces Three Month Follow-Up Data from MOJAVE Non- Randomized Cohort Confirming Significant Improvement in Diuretic Response and Virtual Elimination of Loop Diuretics Following DSR Therapy	25.03.
Sequana Medical Raises EUR11.5 Million via Share Placement	21.03.
Sequana Medical's Premarket Application for Alfapump Accepted by US FDA; Shares Rise	29.01.
Sequana Medical Receives New US Reimbursement Codes for Alfapump System	03.01.
Belgium's Sequana Medical Seeks US FDA Premarket Approval for Liver Ascites Treatment Device	28.12.
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure	29.11.
Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director	10.11.
Transcript : Sequana Medical NV - Special Call	19.10.23
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome	18.10.23
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2023	14.09.23
Transcript : Sequana Medical NV, H1 2023 Earnings Call, Sep 14, 2023	14.09.23
Belgium’s Sequana Medical Enrolls First Patient in Early-stage Trial for Treatment of Chronic Heart Failure	10.07.23
Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure	10.07.23
Sequana Medical NV Announces Completion of 1,000th Alfapump Implant	06.07.23
Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director	26.06.23
Transcript : Sequana Medical NV - Special Call	21.06.23
Sequana Medical Secures US FDA Clearance for Investigational New Drug Application	02.05.23
Belgium's Sequana Medical Raises EUR16 Million to Advance Clinical Programs	25.04.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sequana Medical N.V.

Aktien

A2PD78

BE0974340722

SEQUA

Andere Sprachen

Filter